US-CONGRESS HR7970: STOP Nitazenes Act
HR 7970, the STOP Nitazenes Act, has been forwarded to the full committee. This bill aims to permanently schedule nitazene compounds as Schedule I controlled substances, impacting manufacturing, handling, and distribution of these drugs.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that handle or may encounter nitazene compounds. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Upon enactment (unknown date; monitor committee markup and floor votes).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill progresses toward making all nitazene compounds Schedule I, imposing strict DEA quotas, registration, and security requirements, and potentially disrupting supply chains for any products containing or related to these substances.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that handle or may encounter nitazene compounds.
What you must do
Review current and planned products for nitazene content; assess DEA registration and quota needs; prepare for potential rescheduling compliance.
Deadline
Upon enactment (unknown date; monitor committee markup and floor votes).
Source: https://www.congress.gov/bill/119th-congress/house-bill/7970
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS S4189: INSULIN Act of 2026
- FDA finalizes rule change allowing mail-order abortion pills - PBS
- US-CONGRESS HR4993: Joe Fiandra Access to Home Infusion Act of 2025
- Justice Department eases restrictions on some marijuana products - CBS News
- Experimental Drugs Without FDA Approval Are Now Legal in Montana - VICE